Latest news with #AdventInternational
Bloomberg
4 days ago
- Business
- Bloomberg
Europe Set to Benefit as Deals Rotate Away From US: Advent
John Maldonado, managing partner at Advent International, discusses the private equity deals climate and says Europe is set to benefit as investment rotates away from the US. Advent has been busy in the region, with several deals signed or close to being finalized in recent weeks, Maldonado says. He speaks with Bloomberg's Kriti Gupta from the sidelines of the SuperReturn conference in Berlin. (Source: Bloomberg)
&w=3840&q=100)
Business Standard
16-05-2025
- Business
- Business Standard
Eureka Forbes Q4 results: Profit doubles to Rs 49.5 cr, revenue up 10.6%
Health and hygiene products maker Eureka Forbes Ltd on Friday reported a twofold increase in its consolidated net profit to Rs 49.48 crore in the March quarter of 2024-25. The company had posted a net profit of Rs 21.38 crore in the January-March quarter a year ago, according to a regulatory filing by the firm now controlled by private equity firm Advent International. Its revenue from operations was up 10.67 per cent to Rs 612.65 crore during the quarter under review. It was at Rs 553.56 crore in the corresponding quarter. Eureka Forbes' total expenses increased 7 per cent to Rs 551.75 crore in the March quarter. Total income, which includes other income, was up 11 at Rs 617.04 crore in the quarter. Commenting on the results, the company's MD and CEO Pratik Pota said: "In Q4, continuing business revenue grew by 10.9% YoY, and this was the sixth successive quarter of double-digit growth. Led by operating leverage, EBITDA margins touched 13 per cent for the first time." The momentum in our product business sustained and our innovations and growth investments helped the products grow in high teens, he said. In FY25, Eureka Forbes' profit increased by 72 per cent to Rs 164.41 crore from Rs 95.64 crore a year ago. Total income rose by 11.53 per cent to Rs 2,451.47 crore compared to the previous year. This is the "second full year of transformation with yet another quarter of double-digit growth and lifetime high profitability," said Pota. Eureka Forbes is now promoted by Lunolux, which is a special purpose vehicle established by AI Global Investments (Cyprus) PCC Ltd, which acts as the investment hub for Asia for all the funds managed by Advent International. Shapoorji Pallonji Group, the former promoter exited the company in 2022. Over outlook, Pota said: "Looking ahead, our focus will be on driving service revenue. Several transformation initiatives have been underway, and I am pleased to report that we are seeing green shoots in our service revenue. At the same time, we will stay the course on innovations, step up our growth investments further, and drive margin improvement." Shares of Eureka Forbes Ltd on Friday settled at Rs 594.85 on BSE, up 9.97 per cent from the previous close.
Economic Times
16-05-2025
- Business
- Economic Times
Eureka Forbes Q4 Results: Profit up twofold to Rs 49 crore, revenue up 10%
Health and hygiene products maker Eureka Forbes Ltd on Friday reported a twofold increase in its consolidated net profit to Rs 49.48 crore in the March quarter of 2024-25. The company had posted a net profit of Rs 21.38 crore in the January-March quarter a year ago, according to a regulatory filing by the firm now controlled by private equity firm Advent International. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Health and hygiene products maker Eureka Forbes Ltd on Friday reported a twofold increase in its consolidated net profit to Rs 49.48 crore in the March quarter of 2024-25. The company had posted a net profit of Rs 21.38 crore in the January-March quarter a year ago, according to a regulatory filing by the firm now controlled by private equity firm Advent revenue from operations was up 10.67 per cent to Rs 612.65 crore during the quarter under review. It was at Rs 553.56 crore in the corresponding Forbes' total expenses increased 7 per cent to Rs 551.75 crore in the March quarter. Total income, which includes other income, was up 11 at Rs 617.04 crore in the on the results, the company's MD and CEO Pratik Pota said: "In Q4, continuing business revenue grew by 10.9% YoY, and this was the sixth successive quarter of double-digit growth. Led by operating leverage, EBITDA margins touched 13 per cent for the first time."The momentum in our product business sustained and our innovations and growth investments helped the products grow in high teens, he FY25, Eureka Forbes' profit increased by 72 per cent to Rs 164.41 crore from Rs 95.64 crore a year ago. Total income rose by 11.53 per cent to Rs 2,451.47 crore compared to the previous is the "second full year of transformation with yet another quarter of double-digit growth and lifetime high profitability," said Forbes is now promoted by Lunolux, which is a special purpose vehicle established by AI Global Investments (Cyprus) PCC Ltd, which acts as the investment hub for Asia for all the funds managed by Advent International. Shapoorji Pallonji Group, the former promoter exited the company in outlook, Pota said: "Looking ahead, our focus will be on driving service revenue. Several transformation initiatives have been underway, and I am pleased to report that we are seeing green shoots in our service revenue. At the same time, we will stay the course on innovations, step up our growth investments further, and drive margin improvement." Shares of Eureka Forbes Ltd on Friday settled at Rs 594.85 on BSE, up 9.97 per cent from the previous close.
Time of India
23-04-2025
- Business
- Time of India
India gets largest PE investment in healthcare sector in Asia-Pacific region during 2024: Report
New Delhi: With 26 per cent of the deal volume, India has emerged as the largest private equity buyout in the healthcare sector in the Asia-Pacific region in 2024, said a report by the global private investment firm Bain and Capital. The wider Asia-Pacific market, however, grapples with a decline in buyout activity, with regional volumes plummeting by nearly 49 per cent. "India also appears more resilient to deal downturns than other countries in the region, with buyout volumes dipping only 18 per cent from 2023, vs. a nearly 49 percent drop across Asia-Pacific overall", said the report This growth can be attributed to a combination of buoyant capital markets, strong economic fundamentals, and a burgeoning investor confidence, fuelled by successful private equity exits, such as Advent International's USD 1.6 billion sale of BSV Group to Mankind Pharma. "Successful PE exits with strong returns, such as Advent International's USD 1.6 billion sale of BSV Group to Mankind Pharma, have also validated India's buyout market, making it more attractive for future investment," the report added. Strong growth is projected to continue in India's healthcare sector, with healthcare spending expected to reach USD 320 billion by 2028. In India, over the past two years, investments have come in the provider and related services space and biopharma and related services, with a sharper focus on provider deals. In the provider space, investments have gravitated to hospitals, clinics, and supporting services. The report highlighted that the India has consistently delivered favourable returns and has enabled a range of successful exits for PE firms through initial public offerings (boosted by strong public markets), strategic acquisitions (bolstered by acquirers' strong balance sheets), and sponsor-to-sponsor deals (such as KKR's USD 839 million acquisition of Healthium Medtech from Apax Funds). "With a proven track record, favourable macroeconomic conditions, and a diverse healthcare landscape, India is expected to remain a prime investment location for PE firms," the report added.
The Print
23-04-2025
- Business
- The Print
India gets largest PE investment in healthcare sector in Asia-Pacific region during 2024: Report
The wider Asia-Pacific market, however, grapples with a decline in buyout activity, with regional volumes plummeting by nearly 49 per cent. New Delhi [India], April 23 (ANI): With 26 per cent of the deal volume, India has emerged as the largest private equity buyout in the healthcare sector in the Asia-Pacific region in 2024, said a report by the global private investment firm Bain and Capital. 'India also appears more resilient to deal downturns than other countries in the region, with buyout volumes dipping only 18 per cent from 2023, vs. a nearly 49 percent drop across Asia-Pacific overall', said the report This growth can be attributed to a combination of buoyant capital markets, strong economic fundamentals, and a burgeoning investor confidence, fuelled by successful private equity exits, such as Advent International's USD 1.6 billion sale of BSV Group to Mankind Pharma. 'Successful PE exits with strong returns, such as Advent International's USD 1.6 billion sale of BSV Group to Mankind Pharma, have also validated India's buyout market, making it more attractive for future investment,' the report added. Strong growth is projected to continue in India's healthcare sector, with healthcare spending expected to reach USD 320 billion by 2028. In India, over the past two years, investments have come in the provider and related services space and biopharma and related services, with a sharper focus on provider deals. In the provider space, investments have gravitated to hospitals, clinics, and supporting services. The report highlighted that the India has consistently delivered favourable returns and has enabled a range of successful exits for PE firms through initial public offerings (boosted by strong public markets), strategic acquisitions (bolstered by acquirers' strong balance sheets), and sponsor-to-sponsor deals (such as KKR's USD 839 million acquisition of Healthium Medtech from Apax Funds). 'With a proven track record, favourable macroeconomic conditions, and a diverse healthcare landscape, India is expected to remain a prime investment location for PE firms,' the report added. (ANI) This report is auto-generated from ANI news service. ThePrint holds no responsibility for its content.
